← Back to headlines
Ascendis Pharma Upgraded to Outperform by BMO
Ascendis Pharma has received an 'outperform' rating from BMO, citing growth in its TransCon platform.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
